Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC)

Data underscore long-term safety and effectiveness in pediatric and adult NPC patients

Feb. 4, 2026 at 7:39am

Got story updates? Submit your updates here. ›

Zevra Therapeutics, Inc. announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLD Symposium™. The data demonstrate that arimoclomol was well tolerated and stabilized disease progression in the overall cohort, with changes in clinical severity scores remaining below thresholds for clinically meaningful worsening, supporting sustained benefit across a broad patient population, including adults.

Why it matters

These data reinforce the potential of MIPLYFFA to meaningfully stabilize disease progression in NPC patients, including adults who have historically had limited clinical data. As controlled clinical trial results are supported by long-term real-world experience, Zevra continues to strengthen the understanding of MIPLYFFA's impact and advance its mission to deliver meaningful therapies for people living with rare diseases.

The details

The key data highlights include: 1) Four years of real-world data from the U.S. Early Access Program demonstrating that arimoclomol was well tolerated and stabilized disease progression in the overall cohort; 2) Long-term real-world evidence from clinical practice, including data from participants with up to four years of follow-up, showing durable treatment effects of arimoclomol; 3) A post hoc efficacy analysis of the randomized, placebo-controlled NPC002 trial, where arimoclomol combined with miglustat demonstrated a statistically significant slowing of disease progression compared to placebo as early as three months after treatment initiation; and 4) A four-year dataset on the impact of arimoclomol in adult NPC patients, providing the most robust insights to date in this understudied population.

  • The data was presented at the 22nd Annual WORLD Symposium™ on February 4, 2026.

The players

Zevra Therapeutics, Inc.

A commercial-stage company focused on providing therapies for people living with rare disease, and the developer of MIPLYFFA® (arimoclomol).

Adrian Quartel, M.D., FFPM

Zevra's Chief Medical Officer.

Got photos? Submit your photos here. ›

What they’re saying

“These data highlight MIPLYFFA's potential to meaningfully stabilize disease progression across a broad spectrum of NPC patients, including adults who have historically had limited clinical data.”

— Adrian Quartel, Chief Medical Officer, Zevra Therapeutics

What’s next

Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.

The takeaway

The positive real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) presented at the WORLD Symposium™ underscore the potential of this therapy to meaningfully stabilize disease progression in both pediatric and adult NPC patients, providing hope for those living with this rare and progressive neurodegenerative disorder.